$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2022 Q4 Form 10-Q Financial Statement

#000117867022000026 Filed on October 27, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $335.0M $264.3M
YoY Change 29.59% 40.86%
Cost Of Revenue $51.27M $36.51M
YoY Change 36.11% 29.96%
Gross Profit $283.8M $227.8M
YoY Change 28.48% 42.78%
Gross Profit Margin 84.7% 86.19%
Selling, General & Admin $210.3M $235.9M
YoY Change 12.86% 66.01%
% of Gross Profit 74.13% 103.54%
Research & Development $262.0M $245.4M
YoY Change 14.4% 26.11%
% of Gross Profit 92.34% 107.71%
Depreciation & Amortization $14.31M $10.60M
YoY Change 25.81% -10.06%
% of Gross Profit 5.04% 4.65%
Operating Expenses $472.4M $481.2M
YoY Change 13.71% 42.95%
Operating Profit -$188.6M -$258.0M
YoY Change -3.06% 42.03%
Interest Expense -$32.92M $41.08M
YoY Change -45.74% 2.01%
% of Operating Profit
Other Income/Expense, Net $14.52M -$147.9M
YoY Change -386.65% 555.63%
Pretax Income -$207.0M -$405.9M
YoY Change -20.47% 98.76%
Income Tax $472.0K -$23.00K
% Of Pretax Income
Net Earnings -$207.5M -$405.9M
YoY Change -19.72% 98.48%
Net Earnings / Revenue -61.93% -153.58%
Basic Earnings Per Share -$3.32
Diluted Earnings Per Share -$1.68 -$3.32
COMMON SHARES
Basic Shares Outstanding 123.0M shares 120.0M shares
Diluted Shares Outstanding 122.2M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.164B $2.242B
YoY Change -8.63% -0.58%
Cash & Equivalents $866.4M $1.073B
Short-Term Investments $1.298B $1.169B
Other Short-Term Assets $132.9M $125.5M
YoY Change 50.91% 15.65%
Inventory $129.0M $115.5M
Prepaid Expenses
Receivables $238.0M $184.5M
Other Receivables $32.34M $21.93M
Total Short-Term Assets $2.692B $2.691B
YoY Change -4.14% 0.58%
LONG-TERM ASSETS
Property, Plant & Equipment $523.5M $514.8M
YoY Change 4.29% 6.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $66.09M $61.40M
YoY Change 9.78% 74.09%
Total Long-Term Assets $854.1M $844.4M
YoY Change 2.32% 5.95%
TOTAL ASSETS
Total Short-Term Assets $2.692B $2.691B
Total Long-Term Assets $854.1M $844.4M
Total Assets $3.546B $3.535B
YoY Change -2.66% 1.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $98.09M $40.57M
YoY Change 33.6% 1.31%
Accrued Expenses $545.5M $510.6M
YoY Change 38.03% 31.4%
Deferred Revenue $42.11M $144.2M
YoY Change -71.83% 25.35%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $767.9M $772.8M
YoY Change 10.38% 26.55%
LONG-TERM LIABILITIES
Long-Term Debt $1.017B $1.016B
YoY Change 50.5% 134.2%
Other Long-Term Liabilities $212.6M $183.0M
YoY Change 114.81% 139.37%
Total Long-Term Liabilities $212.6M $183.0M
YoY Change 114.81% 139.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $767.9M $772.8M
Total Long-Term Liabilities $212.6M $183.0M
Total Liabilities $3.705B $3.603B
YoY Change 21.26% 32.63%
SHAREHOLDERS EQUITY
Retained Earnings -$6.569B -$6.362B
YoY Change 20.8% 22.82%
Common Stock $6.456B $6.338B
YoY Change 6.54% 6.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$158.2M -$67.64M
YoY Change
Total Liabilities & Shareholders Equity $3.546B $3.535B
YoY Change -2.66% 1.81%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$207.5M -$405.9M
YoY Change -19.72% 98.48%
Depreciation, Depletion And Amortization $14.31M $10.60M
YoY Change 25.81% -10.06%
Cash From Operating Activities -$132.0M -$115.3M
YoY Change -12.1% -13.99%
INVESTING ACTIVITIES
Capital Expenditures $21.63M -$16.51M
YoY Change -198.85% -36.65%
Acquisitions
YoY Change
Other Investing Activities -$118.3M $330.4M
YoY Change -69.79% -631.11%
Cash From Investing Activities -$139.9M $313.9M
YoY Change -66.16% -455.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 63.44M 297.0M
YoY Change -78.3% -48.24%
NET CHANGE
Cash From Operating Activities -132.0M -115.3M
Cash From Investing Activities -139.9M 313.9M
Cash From Financing Activities 63.44M 297.0M
Net Change In Cash -208.5M 495.6M
YoY Change -23.15% 40.99%
FREE CASH FLOW
Cash From Operating Activities -$132.0M -$115.3M
Capital Expenditures $21.63M -$16.51M
Free Cash Flow -$153.6M -$98.77M
YoY Change 19.77% -8.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001178670
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36407
dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0602661
dei Entity Address Address Line1
EntityAddressAddressLine1
675 West Kendall Street,
dei Entity Address Address Line2
EntityAddressAddressLine2
Henri A. Termeer Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
551-8200
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
ALNY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
123028234 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1073228000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
819975000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1169050000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1548617000 usd
CY2022Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
23051000 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
66972000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
184513000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
198571000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
115489000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
86363000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
125516000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
88078000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
2690847000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2808576000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
514821000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
501958000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
218802000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
231675000 usd
CY2022Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
49389000 usd
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
40891000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61396000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
60204000 usd
CY2022Q3 us-gaap Assets
Assets
3535255000 usd
CY2021Q4 us-gaap Assets
Assets
3643304000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
40572000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
73426000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
510579000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
395174000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
41581000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
40548000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
144208000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
149483000 usd
CY2022Q3 alny Royalty Liability Current
RoyaltyLiabilityCurrent
35851000 usd
CY2021Q4 alny Royalty Liability Current
RoyaltyLiabilityCurrent
37079000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
772791000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
695710000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
266323000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
281347000 usd
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
132930000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
152360000 usd
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1015975000 usd
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 usd
CY2022Q3 alny Long Term Debt Excluding Convertible Debt
LongTermDebtExcludingConvertibleDebt
0 usd
CY2021Q4 alny Long Term Debt Excluding Convertible Debt
LongTermDebtExcludingConvertibleDebt
675697000 usd
CY2022Q3 alny Royalty Liability Noncurrent
RoyaltyLiabilityNoncurrent
1231873000 usd
CY2021Q4 alny Royalty Liability Noncurrent
RoyaltyLiabilityNoncurrent
1151024000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
183001000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98963000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
3602893000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
3055101000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
122991000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122991000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120182000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
120182000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1230000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1202000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
6336771000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
6058453000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-43783000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33259000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6361856000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5438193000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-67638000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
588203000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3535255000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3643304000 usd
CY2022Q3 us-gaap Revenues
Revenues
264306000 usd
CY2021Q3 us-gaap Revenues
Revenues
187633000 usd
us-gaap Revenues
Revenues
702383000 usd
us-gaap Revenues
Revenues
585752000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
36507000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28091000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
94002000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
81370000 usd
CY2022Q3 alny Cost Of Collaboration Manufacturing And Royalties
CostOfCollaborationManufacturingAndRoyalties
4609000 usd
CY2021Q3 alny Cost Of Collaboration Manufacturing And Royalties
CostOfCollaborationManufacturingAndRoyalties
4572000 usd
alny Cost Of Collaboration Manufacturing And Royalties
CostOfCollaborationManufacturingAndRoyalties
23549000 usd
alny Cost Of Collaboration Manufacturing And Royalties
CostOfCollaborationManufacturingAndRoyalties
21110000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
245371000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
194572000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
620976000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
563106000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
235859000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
142075000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
560314000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
434257000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
522346000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
369310000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1298841000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1099843000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-258040000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-181677000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-596458000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-514091000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
41084000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
40274000 usd
us-gaap Interest Expense
InterestExpense
126055000 usd
us-gaap Interest Expense
InterestExpense
106205000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-30233000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17715000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120873000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28454000 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-76586000 usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-76586000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-147903000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22559000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-323514000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77751000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-405943000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-204236000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-919972000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-591842000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-23000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
278000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3691000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2522000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-405920000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-204514000 usd
us-gaap Net Income Loss
NetIncomeLoss
-923663000 usd
us-gaap Net Income Loss
NetIncomeLoss
-594364000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.32
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.32
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122166000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122166000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
119141000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
119141000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121158000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121158000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118005000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118005000 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-405920000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-204514000 usd
us-gaap Net Income Loss
NetIncomeLoss
-923663000 usd
us-gaap Net Income Loss
NetIncomeLoss
-594364000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2053000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-64000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11004000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-312000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
460000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1857000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
377000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
9530000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-34000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-58000 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-103000 usd
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-174000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1559000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1851000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10524000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9392000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-407479000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-202663000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-934187000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-584972000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
588203000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28059000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30051000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4806000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-240341000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
401166000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13892000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
8090000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34453000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4159000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-277402000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
176040000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153276000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129133000 usd
CY2022Q3 alny Purchases Of Capped Calls Related To Convertible Senior Notes
PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes
-118611000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1559000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-405920000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-67638000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1016247000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47034000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56295000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6905000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-200291000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
926190000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75449000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
7718000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32928000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
636000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-189559000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
853362000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
71499000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33695000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1851000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-204514000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
755893000 usd
us-gaap Net Income Loss
NetIncomeLoss
-923663000 usd
us-gaap Net Income Loss
NetIncomeLoss
-594364000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
30157000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
36192000 usd
alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
30508000 usd
alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
32051000 usd
alny Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
79621000 usd
alny Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
87197000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
187882000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
121135000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-40108000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
61273000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-76586000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
-70776000 usd
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
-19654000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
20607000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
15568000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7672000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42350000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15158000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15655000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
47194000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
48765000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
89152000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
48738000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-31718000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-29586000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-24632000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-60094000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-409296000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-491552000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50424000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54486000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1253584000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
973146000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1626848000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1172100000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
89951000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
25975000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
98451000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
26140000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
5075000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
4198000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
309265000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
140105000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
202646000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
201227000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1016888000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
762107000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
alny Purchases Of Capped Calls Related To Convertible Senior Notes
PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes
118611000 usd
alny Purchases Of Capped Calls Related To Convertible Senior Notes
PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes
0 usd
alny Proceeds From Sale Of Royalties Interest
ProceedsFromSaleOfRoyaltiesInterest
0 usd
alny Proceeds From Sale Of Royalties Interest
ProceedsFromSaleOfRoyaltiesInterest
500000000 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
23500000 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
16100000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
250000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-12500000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
362316000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
954827000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9049000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5968000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
253236000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
597412000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
822153000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
499046000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1075389000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1096458000 usd
us-gaap Interest Paid Net
InterestPaidNet
43932000 usd
us-gaap Interest Paid Net
InterestPaidNet
17703000 usd
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2022, we have five products that have received marketing approval, including one partnered product, and multiple late-stage investigational programs advancing towards potential commercialization. As of September 30, 2022, we generated worldwide product revenues from four commercialized products, ONPATTRO, GIVLAARI, OXLUMO and AMVUTTRA, primarily in the U.S., Europe and Japan.</span></div>
CY2022Q3 alny Number Of Marketed Products
NumberOfMarketedProducts
5 product
CY2022Q3 alny Number Of Partnered Products
NumberOfPartneredProducts
1 product
CY2022Q3 alny Number Of Commercialized Products
NumberOfCommercializedProducts
4 product
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1639000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1603615000 usd
CY2022Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
21933000 usd
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
73266000 usd
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
73625000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
88627000 usd
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
11700000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
17000000 usd
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
12700000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
65200000 usd
CY2022Q3 alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-2300000 usd
alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-9700000 usd
CY2021Q3 alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-3300000 usd
alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-12700000 usd
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21483000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1250762000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
38000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12672000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1238128000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1605245000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1169050000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1548617000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
69078000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54998000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1238128000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1603615000 usd
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
17718000 usd
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
14754000 usd
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
102447000 usd
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
100942000 usd
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7005000 usd
CY2022Q3 alny Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
141648000 usd
CY2021Q4 alny Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
122701000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1073228000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1093991000 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
2161000 usd
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
2467000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1075389000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1096458000 usd
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
383000 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
10907000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10524000 usd
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
9311000 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-81000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9392000 usd
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.13
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
128118000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33367000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
187882000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
121135000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15974000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12961000 shares

Files In Submission

Name View Source Status
0001178670-22-000026-index-headers.html Edgar Link pending
0001178670-22-000026-index.html Edgar Link pending
0001178670-22-000026.txt Edgar Link pending
0001178670-22-000026-xbrl.zip Edgar Link pending
alny-20220930.htm Edgar Link pending
alny-20220930.xsd Edgar Link pending
alny-20220930_g1.gif Edgar Link pending
alny2022q310-qex311.htm Edgar Link pending
alny2022q310-qex312.htm Edgar Link pending
alny2022q310-qex321.htm Edgar Link pending
alny2022q310-qex322.htm Edgar Link pending
alny2022q310-qex41.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image1a.jpg Edgar Link pending
image2a.jpg Edgar Link pending
image3a.jpg Edgar Link pending
image4a.jpg Edgar Link pending
image5a.jpg Edgar Link pending
imagea.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
alny-20220930_def.xml Edgar Link unprocessable
alny-20220930_lab.xml Edgar Link unprocessable
alny-20220930_pre.xml Edgar Link unprocessable
alny-20220930_cal.xml Edgar Link unprocessable
alny-20220930_htm.xml Edgar Link completed